1-2 of 2
Francesca Ferrari
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression

Free
Jonathan Black, Gulden Menderes, Stefania Bellone, Carlton L. Schwab, Elena Bonazzoli, Francesca Ferrari, Federica Predolini, Christopher De Haydu, Emiliano Cocco, Natalia Buza, Pei Hui, Serena Wong, Salvatore Lopez, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Babak Litkouhi, Peter E. Schwartz, Peter Goedings, Patrick H. Beusker, Miranda M.C. van der Lee, C. Marco Timmers, Wim H.A. Dokter, Alessandro D. Santin
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (8): 1900–1909.
https://doi.org/10.1158/1535-7163.MCT-16-0163
Published: 03 August 2016
View article titled, SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
Open the PDF for SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression in another window
Includes: Supplementary data
Journal Articles

Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo

Free
Salvatore Lopez, Emiliano Cocco, Jonathan Black, Stefania Bellone, Elena Bonazzoli, Federica Predolini, Francesca Ferrari, Carlton L. Schwab, Diana P. English, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Peter E. Schwartz, Corrado Terranova, Roberto Angioli, Alessandro D. Santin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (11): 2519–2526.
https://doi.org/10.1158/1535-7163.MCT-15-0383
Published: 03 November 2015
View article titled, Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo
Open the PDF for Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo in another window
Includes: Supplementary data